41 results
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
21 Dec 22
Current report (foreign)
6:01am
on April 1, 2023 ⚫ Global life science ecosystem expected to further thrive, building on founding vision and mission ⚫ Shonan iPark is a major R&D … , Shonan iPark has been operating its facilitie s and c onduc ting open innovation promotion projec ts with a mission of “Building a life science
6-K
TAK
Takeda Pharmaceutical Co
16 Jul 19
Current report (foreign)
8:50am
Profile and Other Matters
Basic Views
Takeda’s mission is to “strive towards Better Health and Brighter Future for people worldwide through leading … innovation in medicine.” In line with this mission, Takeda is establishing a management framework appropriate for a R&D-driven biopharmaceutical company
6-K
TAK
Takeda Pharmaceutical Co
14 Jun 19
Current report (foreign)
6:17am
. Basic Views
Update
Takeda’s mission is to “strive towards Better Health and Brighter Future for people worldwide through leading innovation … in medicine.” In line with this mission, Takeda is establishing a management framework appropriate for aR&D-driven biopharmaceutical company that operates
6-K
TAK
Takeda Pharmaceutical Co
29 Jul 20
Current report (foreign)
6:07am
Profile and Other Matters
1.Basic Views
Takeda’s mission is to “strive towards Better Health and Brighter Future for people worldwide through leading … innovation in medicine.” In line with this mission, Takeda is establishing a management framework appropriate for a R&D-driven biopharmaceutical
6-K
TAK
Takeda Pharmaceutical Co
31 Jan 19
Current report (foreign)
6:07am
Profile and Other Matters
Basic Views
Takeda’s mission is to “strive towards Better Health and Brighter Future for people worldwide through leading … innovation in medicine.” In line with this mission, Takeda is establishing a management framework appropriate for a world-class pharmaceutical company
6-K
EX-99.1
zdca50 z6w
10 Jan 20
Better Health, Brighter Future 2019 SUSTAINABLE VALUE REPORT Takeda Pharmaceutical Company Limited
6:36am
6-K
hbf4vj
6 Oct 21
Current report (foreign)
6:03am
6-K
c7corp8rme
19 Jul 21
Current report (foreign)
6:02am
6-K
rqjj5g
1 Nov 21
Current report (foreign)
6:04am
6-K
qrh8juzh
29 May 20
Current report (foreign)
6:20am
6-K
qzn592bco8egk db04k8
1 Apr 22
Current report (foreign)
6:14am
6-K
ej96jkw81vcq 7ke
21 Dec 22
Current report (foreign)
6:01am
SC TO-T/A
EX-99
67sf8a15
6 Jun 18
Third party tender offer statement (amended)
4:39pm
6-K
EX-99.1
p4ck1 t20
31 May 22
Current report (foreign)
6:14am
6-K
iwvsi4e
18 Jun 19
Current report (foreign)
6:09am
6-K
0p1pzca7i
17 Jun 19
Current report (foreign)
6:08am
6-K
EX-1
2lcyy4yn227f8 lkzmx
27 May 20
Current report (foreign)
6:03am
6-K
EX-99.1
zemzbflaoa6co41mn3
31 May 22
Current report (foreign)
12:00am
6-K
zhzw2chv8da9f6j5y9
30 May 19
Current report (foreign)
10:26am
20FR12B/A
EX-1.2
sksv1 nz4h41d8z
17 Dec 18
Initial registration of securities (foreign private issuers) (amended)
6:14am